Ralph Tiedt

Company: Monte Rosa Therapeutics

Job title: VP Biology

Seminars:

Panel Discussion: Assessing Targeted Protein Degradation’s Ability to be Both Selective & Safe 9:45 am

How much progress has been made in identifying and utilising tissue-sparing E3 ligases? Are there more ligases to find? How do we effectively identify them? What does existing off-target safety data tell us about degraders’ behaviour in clinic? Are Molecular Glues a ‘safer’ option? Are there other ‘TACs’ that have potential to be safer due…Read more

day: Conference Day One

From Serendipity to Rational Design: Taking Molecular Glue Degraders to New Heights 8:15 am

ShowcasingQuEEN™, a proprietary molecular glue discovery engine generating therapeutics that selectively degrade disease-causing proteins Discussing Monte Rosa’s approach to accelerate Molecular Glue degrader discovery and validation Developing a potent and selective GSPT1-directed Molecular Glue degraderRead more

day: Conference Day One